Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
This new medicine can really help people lose weight, which could change how we treat obesity
These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015
For someone weighing 250 pounds, that could mean an extra 25-35 pounds of weight loss
GLP-1 receptor agonists mimic the natural gut hormone GLP-1 to improve insulin release, lower blood sugar, reduce appetite, support weight loss, and decrease inflammation throughout the body. Which conditions can GLP-1 medications help
Both retatrutide and semaglutide are easy to use, with once-a-week injections making it simple to stick to the treatment plan compared to taking medication every day
